References
- CarlinBISeftelADResnickMIFindlayJFinasteride induced gynecomastiaJ Urol199715825479224349
- WiltonLPearceGEdetEFreemantleSStephensMDMannRDThe safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patientsBr J Urol19967833793848881946
- SchulmanCPommervillePHöfnerKWachsBLong-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasiaBJU Int2006971737916336332
- CoronaGRastrelliGMaseroliEInhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunctionJ Endocrinol Invest2012351091592022777612
- DesgrandchampsFDroupySIraniJSaussineCComenducciAEffect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practiceBJU Int2006981838816831149
- NarulaHSCarlsonHEGynaecomastia-pathophysiology, diagnosis and treatmentNat Rev Endocrinol2014101168469825112235
- DeepinderFBraunsteinGDDrug-induced gynecomastia: an evidence-based reviewExpert Opin Drug Saf201211577979522862307
- MiaoHVerkooijenHMChiaKSIncidence and outcome of male breast cancer: an international population-based studyJ Clin Oncol201129334381438621969512
- Medicines and Healthcare products Regulatory AgencyFinasteride: potential risk of male breast cancer2009 Available from: https://www.gov.uk/drug-safety-update/finasteride-potential-risk-of-male-breast-cancerAccessed November 1, 2014
- U.S. Food and Drug AdministrationPotential Signals of Serious Risks/New Safety Information Identified by the Adverse Event Reporting System (AERS) October–December 20092010 Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm210293Accessed November 1, 2014
- LawsonDHShermanVHollowellJThe general practice research database. Scientific and Ethical Advisory GroupQJM1998914454529709463
- HerrettEGallagherAMBhaskaranKData resource profile: clinical practice research datalink (CPRD)Int J Epidemiol201544382783626050254
- JickSSKayeJAVasilakis-ScaramozzaCValidity of the general practice research databasePharmacotherapy200323568668912741446
- ThompsonIMGoodmanPJTangenCMThe influence of finasteride on the development of prostate cancerN Engl J Med2003349321522412824459
- AndrioleGLBostwickDGBrawleyOWEffect of dutasteride on the risk of prostate cancerN Engl J Med20103621192120220357281
- RoehrbornCGBoylePNickelJCEfficacy and safety of dual inhibitor 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaUrology200260343444112350480
- KaplanSAChungDELeeRKScofieldSTeAEA 5-year retrospective analysis of 5 α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasterideInt J Clin Pract201266111052105523067029
- TrostLSaitzTRHellstromWJGSide effects of 5-alpha reductase inhibitors: a comprehensive reviewSex Med Rev20131244127784557
- BirdSTBrophyJMHartzemaAGDelaneyJAEtminanMMale breast cancer and 5α-reductase inhibitors finasteride and dutasterideJ Urol201319051811181423665270
- DuijnhovenRGStrausSMSouvereinPCLong-term use of 5α-reductase inhibitors and the risk of male breast cancerCancer Causes Control2014251577158225135615
- RobinsonDGarmoHHolmbergLStattinP5-α Reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancerCancer Causes Control20152691289129726109464